Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Viral Mutations00:36

Viral Mutations

32.6K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.6K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

60
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
60

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temperature and developmental stage govern intestinal susceptibility to human coronavirus 229E.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

IgA is necessary and sufficient to prevent norovirus infection in mice.

Science translational medicine·2026
Same author

mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Early-life mucosal T cells direct intestinal stem cell fate via a coordinated developmental program.

bioRxiv : the preprint server for biology·2026
Same author

Detection of serotonin and serotonin related gene reveals unique roles in human intestinal epithelial development.

bioRxiv : the preprint server for biology·2025
Same author

Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice.

Science (New York, N.Y.)·2025
Same journal

Evolution and development of innate immune memory.

Science immunology·2026
Same journal

The evolving biology of T cell memory: A dynamic continuum of function and persistence.

Science immunology·2026
Same journal

Memories that endure.

Science immunology·2026
Same journal

ILC2s shoot 4 making 13s.

Science immunology·2026
Same journal

Molecular and tissue regulation of memory B cells.

Science immunology·2026
Same journal

A breath of fresh AIR in novel CAR T cell design.

Science immunology·2026
See all related articles

Related Experiment Video

Updated: Jul 27, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.9K

Game over for RSV?

Madison S Strine1, Craig B Wilen1

  • 1Department of Immnobiology and Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.

Science Immunology
|June 5, 2023
PubMed
Summary
This summary is machine-generated.

Passive immunization with nirsevimab effectively shields infants from severe respiratory syncytial virus (RSV) disease. This protection does not hinder the development of natural immunity following infection.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Experiment Videos

Last Updated: Jul 27, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.9K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Area of Science:

  • Pediatrics
  • Immunology
  • Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants.
  • Current prevention strategies for RSV are limited, necessitating new interventions.
  • Passive immunization offers a potential prophylactic approach against RSV disease.

Purpose of the Study:

  • To evaluate the efficacy of nirsevimab for preventing severe RSV disease in infants.
  • To assess the impact of nirsevimab on the infant's immune response to subsequent natural RSV infection.

Main Methods:

  • A passive immunization study involving infants receiving nirsevimab.
  • Monitoring for severe RSV disease and assessing immune responses post-infection.

Main Results:

  • Nirsevimab demonstrated significant protection against severe RSV disease.
  • Infants receiving nirsevimab maintained a robust immune response to natural RSV infection, indicating no impairment.

Conclusions:

  • Passive immunization with nirsevimab is a safe and effective method for protecting infants against severe RSV.
  • Nirsevimab does not compromise the infant's ability to develop natural immunity to RSV.